Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Dia
- PDF / 580,508 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 13 Downloads / 252 Views
ORIGINAL RESEARCH
Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United States Lawrence Blonde . Charmi Patel . Bingcao Wu . Yen-Wen Chen . Christopher D. Pericone . Brahim Bookhart
Received: August 3, 2020 / Accepted: October 23, 2020 Ó Springer Healthcare Ltd., part of Springer Nature 2020
ABSTRACT Introduction: While several sodium glucose cotransporter 2 (SGLT2) inhibitors are approved as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus (T2DM), there are no clinical trial data providing head-to-head comparisons of the efficacy and safety of these therapies. Real-world analyses can provide valuable evidence on the effectiveness of competing treatments. This study compared the real-world glycemic effectiveness of SGLT2 inhibitors in individuals with T2DM. Methods: Patients who initiated canagliflozin 300 mg versus empagliflozin 25 mg or dapagliflozin 10 mg were identified from the OptumÒ De-identified ClinformaticsÒ Extended Data Mart–Date of Death database and propensity score matched. Achievement of HbA1c \ 8.0% (Healthcare Effectiveness Data and Information Electronic supplementary material The online version of this article (https://doi.org/10.1007/s12325020-01549-x) contains supplementary material, which is available to authorized users. L. Blonde Department of Endocrinology, Ochsner Medical Center, New Orleans, LA, USA C. Patel (&) B. Wu Y.-W. Chen C. D. Pericone B. Bookhart Janssen Scientific Affairs, LLC, Titusville, NJ, USA e-mail: [email protected]
Set [HEDIS] target) and [ 9.0% (HEDIS poor control) after 6 months of treatment was calculated. Results: Post-baseline HbA1c was similar in the canagliflozin and empagliflozin cohorts (7.65% versus 7.57%), as was percent of patients with HbA1c \ 8.0% or [ 9.0%. Post-baseline HbA1c was lower with canagliflozin versus dapagliflozin (7.58% versus 7.74%; P = 0.0247). The canagliflozin cohort was more likely to achieve HbA1c \ 8.0% than the dapagliflozin cohort (P = 0.0292); the likelihood of achieving HbA1c [ 9.0% was similar. Conclusion: In patients with T2DM, HbA1c outcomes were similar with canagliflozin and empagliflozin. Patients on canagliflozin versus dapagliflozin were more likely to have a lower HbA1c and reach HbA1c \ 8.0% after 6 months. These results may provide important information for clinicians as they decide the appropriate treatment for their patients with T2DM. Keywords: Canagliflozin; Dapagliflozin; Empagliflozin; Glycated hemoglobin; Glycemic efficacy; Type 2 diabetes mellitus
Adv Ther
INTRODUCTION Key Summary Points Why carry out this study? More than 30 million people in the US have diabetes, which is associated with significant long-term medical issues and increased health care costs Sodium glucose co-transporter 2 (SGLT2) inhibitors are approved as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus (T2DM), but there are no clinical tr
Data Loading...
